Related Experiment Video
Updated: Mar 25, 2026
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Prenatal 17-Alpha-Hydroxyprogesterone Caproate Exposure in Twins and Childhood Outcomes: 14-Year Follow-Up of a
Emilie V J van Limburg Stirum1,2, Marjon A de Boer2,3, A C J Ravelli1,2
1Department of Obstetrics and Gynaecology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
Objective:
Long-term child outcomes after intra-uterine exposure to 17-alpha-hydroxyprogesterone caproate (17-OHPC) versus placebo.
Design:
Follow-up of the AMPHIA randomised controlled trial assessing neonatal outcomes after weekly 17-OHPC injections compared to placebo in multiple pregnancies.
Setting:
Multicentre.
Population Or Sample:
Children born in the AMPHIA study.
Methods:
Children were assessed at 11-14 years of age by record linkage and through self-reported, parental and teacher questionnaires. Mean differences or odds ratios (OR) with 95% confidence intervals (95% CI) were calculated with cluster robust standard errors for twins and adjustment for confounders using inverse probability weighting (IPW).
Main Outcome Measures:
Child mortality, educational attainment, cognition, behaviour, gender identity, general health, and a composite of abnormal development.
Results:
Up to 14 years, 60/1356 children had died (n = 24 17-OHPC and n = 36 placebo (OR 0.75 95% CI 0.36-1.53)). Record linkage was completed for 1027/1296 (79%) surviving children (n = 517 17-OHPC and n = 510 placebo). No significant difference was found regarding educational attainment. Detailed developmental outcomes through questionnaires were collected for 303/1296 (23%) surviving children (n = 159 17-OHPC and n = 144 placebo). No differences in cognition, behaviour, gender identity, and general health up to 14 years of age were found between both groups. The composite of abnormal development did not differ between 17-OHPC (23.3%) and placebo (20.1%) groups (OR 1.31 95% CI 0.66-2.56).
Conclusion:
In offspring of women with a multiple pregnancy, the use of 17-OHPC in pregnancy is unlikely to provide positive or negative effects on child outcome related to mortality, educational attainment, cognition and behaviour.
More Related Videos
09:51Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators
Published on: March 21, 2018
19:15Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Related Concept Videos
01:07Teratogenicity
01:24Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
01:20Gene-Environment Interactions
01:29Drug Dosing: Infants and Children
02:30Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...